Health Leaders Consider Tighter Rules on Drug Ads Aimed at Consumers
A report from the Make America Healthy Again (MAHA) Commission was delayed earlier this month, but leaked documents reveal plans […]
FDA Gives Fast-Track Status to New Lung Cancer Treatment
The US Food and Drug Administration (FDA) has given special recognition to a new experimental drug called izalontamab brengitecan (iza-bren).
Pharmaceutical News
Eli Lilly’s Neuroscience Leader Anne White to Retire After 30 Years
Anne White, the Executive Vice President and President of Lilly Neuroscience at Eli Lilly and Company, will retire at the
New Blood Test Could Replace Tissue Biopsies for Cancer Patients
In this project, ANGLE’s research team will use the Parsortix system to collect cancer cells from the blood of cancer
Study Shows How Better Screening Helps People with Substance Use Disorder Fight Infections
The US Centers for Disease Control and Prevention (CDC) reports that about one in six Americans struggles with substance use
AstraZeneca’s Breakthrough in Lung Cancer Treatment: Targeting the EGFR Mutation
AstraZeneca’s journey in lung cancer treatment began in 2003 with a drug called Iressa, which targeted a specific gene mutation
Pharmaceutical News
ICH Seeks Public Input on New Guidelines for Drug Impurities from Leachables
The International Council for Harmonisation (ICH) has opened a public consultation on its draft guidelines for managing drug impurities caused
Teva’s AJOVY Now Approved for Migraine Prevention in Kids and Teens
Teva Pharmaceuticals has received FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraines in children and adolescents
Eli Lilly’s Mounjaro Shows Strong Results in Heart Health Study for Diabetes Patients
Eli Lilly has shared promising results from its large-scale study comparing Mounjaro (tirzepatide) with Trulicity (dulaglutide) in adults with type
Big Pharma’s Strategy: Dealmaking to Stay Ahead Despite Challenges
Even with recent uncertainties, big pharmaceutical companies continue to focus on business deals to keep growing. Factors like upcoming tariffs,